About Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals develops new chemical entities targeting the root causes of depression, anxiety, and stress-related disorders through advanced medicinal chemistry and an AI-powered discovery platform. Their therapies include rapid-acting, non-hallucinogenic neuroplastogens and safer ibogaine analogs, offering improved efficacy and safety profiles for patients.

```xml <problem> Current treatments for depression, anxiety, and stress-related disorders often focus on symptom management rather than addressing the underlying neurological causes. Existing therapies may have slow onset, limited efficacy, or undesirable side effects, such as dissociative effects or cardiac safety concerns. </problem> <solution> Gilgamesh Pharmaceuticals is developing a pipeline of novel, rapid-acting therapies that target the root causes of neurological diseases. Utilizing advanced medicinal chemistry and an AI-powered discovery platform, they are creating new chemical entities (NCEs) with improved efficacy and safety profiles. Their focus is on precision psychiatric therapies that move beyond symptom management to provide rapid-acting and long-lasting relief. </solution> <features> - NMDAR Antagonists: Orally bioavailable, rapid-acting NCEs designed to minimize dissociative effects for the treatment of depression and other indications. - 5-HT2AR Agonists: Rapid-acting antidepressant NCEs with optimized duration of effect and improved cardiac safety profiles for depression and other indications. - Non-Hallucinogenic Neuroplastogens: Orally bioavailable, rapid-acting NCEs designed to be non-hallucinogenic for the treatment of depression and other indications. - Safer Ibogaine Analogs: NCEs designed for rapid and sustained efficacy with an improved cardiac safety profile for opioid use disorder and other indications. - AI-powered discovery and translational platform to accelerate the creation of novel precision psychiatric therapies. </features> <target_audience> The primary target audience includes individuals suffering from depression, anxiety, stress-related disorders, and opioid use disorder, as well as healthcare providers seeking more effective and safer treatment options. </target_audience> ```

What does Gilgamesh Pharmaceuticals do?

Where is Gilgamesh Pharmaceuticals located?

Gilgamesh Pharmaceuticals is based in East New York, United States.

When was Gilgamesh Pharmaceuticals founded?

Gilgamesh Pharmaceuticals was founded in 2019.

How much funding has Gilgamesh Pharmaceuticals raised?

Gilgamesh Pharmaceuticals has raised 82559845.

Location

East New York, United States

Founded

2019

Funding

82559845

Employees

33 employees

Major Investors

Alumni Ventures, Y Combinator, Bossa Invest, Gaingels, Pioneer Fund

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Gilgamesh Pharmaceuticals

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

gilgameshpharmaceutical.com 5K+

Founded 2019 – East New York, United States

Funding

Estimated Funding

$50M+

Major Investors

Alumni Ventures, Y Combinator, Bossa Invest, Gaingels, Pioneer Fund

Team (30+)

No team information available.

Company Description

Problem

Current treatments for depression, anxiety, and stress-related disorders often focus on symptom management rather than addressing the underlying neurological causes. Existing therapies may have slow onset, limited efficacy, or undesirable side effects, such as dissociative effects or cardiac safety concerns.

Solution

Gilgamesh Pharmaceuticals is developing a pipeline of novel, rapid-acting therapies that target the root causes of neurological diseases. Utilizing advanced medicinal chemistry and an AI-powered discovery platform, they are creating new chemical entities (NCEs) with improved efficacy and safety profiles. Their focus is on precision psychiatric therapies that move beyond symptom management to provide rapid-acting and long-lasting relief.

Features

NMDAR Antagonists: Orally bioavailable, rapid-acting NCEs designed to minimize dissociative effects for the treatment of depression and other indications.

5-HT2AR Agonists: Rapid-acting antidepressant NCEs with optimized duration of effect and improved cardiac safety profiles for depression and other indications.

Non-Hallucinogenic Neuroplastogens: Orally bioavailable, rapid-acting NCEs designed to be non-hallucinogenic for the treatment of depression and other indications.

Safer Ibogaine Analogs: NCEs designed for rapid and sustained efficacy with an improved cardiac safety profile for opioid use disorder and other indications.

AI-powered discovery and translational platform to accelerate the creation of novel precision psychiatric therapies.

Target Audience

The primary target audience includes individuals suffering from depression, anxiety, stress-related disorders, and opioid use disorder, as well as healthcare providers seeking more effective and safer treatment options.